New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
19:37 EDTBCRC.R. Bard receives favorable recommendation from FDA panel for Lutonix DCB
C. R. Bard announced that the FDA Circulatory System Devices Advisory Panel provided a unanimous favorable recommendation to FDA for use of the Lutonix Drug Coated Balloon PTA Catheter, or DCB, in the U.S. The Lutonix DCB is currently under review by FDA for improving luminal diameter and reducing the incidence of restenosis for the treatment of obstructive de novo or non-stented restenotic lesions in native femoropopliteal arteries with reference vessel diameters of 4 mm to 6 mm. If approved, it is expected that the Lutonix DCB will be the first and only FDA-approved DCB available in the U.S.
News For BCR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:37 EDTBCRC.R. Bard upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill upgraded C.R. Bard two notches to Buy from Underperform and increased its price target to $200 following Q1 results. The firm sees upside to Bard's drug eluting balloon franchise following the report and recent survey results, and expects the company to utilize its under leverage balance sheet in 2015.
April 23, 2015
17:40 EDTBCRC.R. Bard sees Q2 EPS $2.15-$2.19, consensus $2.18
Subscribe for More Information
17:29 EDTBCRC.R. Bard sees FY15 EPS $8.95-$9.05, consensus $9.00
Guidance provided on Q1 earnings conference call.
16:18 EDTBCRC.R. Bard reports Q1 adjusted EPS $2.10, consensus $2.07
Reports Q1 revenue $819.7M, consensus $813.88M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use